Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Insusense Therapeutics

Insusense Therapeutics?uq=UG6efJS6
2010 FOUNDED
PRIVATE STATUS
Later Stage VC LATEST DEAL TYPE
$2.26M LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of novel drugs designed to provide treatment for diabetes and other metabolic diseases such as obesity. The company's novel drugs help to control sugar level in the body and have the potential to treat diabetes, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Primary Office
  • Skolevangs Alle 1 B
  • Risskov
  • 8240 Aarhus
  • Denmark

+45 89 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Insusense Therapeutics’s full profile, request a free trial.

Insusense Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 22-Oct-2015 $2.26M 00.000 Completed Generating Revenue
1. Early Stage VC 05-Mar-2013 00.000 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Insusense Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Lundbeckfonden Limited Partner Minority 000 0000 000000 0
Lundbeckfond Emerge Venture Capital Minority 000 0000 000000 0

Insusense Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Anders Nykjaer Ph.D Co-Founder & Chief Scientific Officer
Karen Pedersen Ph.D Co-Founder
Mads Kjølby Ph.D Co-Founder
Christian Elling Ph.D Chief Executive Officer